Ecopipam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ecopipam
Accession Number
DB12273
Type
Small Molecule
Groups
Investigational
Description

Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Ecopipam Hydrochloride5X1J3190JI190133-94-9APFMVAHRFWBCDG-JUOYHRLASA-N
Categories
UNII
0X748O646K
CAS number
112108-01-7
Weight
Average: 313.83
Monoisotopic: 313.123342
Chemical Formula
C19H20ClNO
InChI Key
DMJWENQHWZZWDF-PKOBYXMFSA-N
InChI
InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
IUPAC Name
(1R,11S)-5-chloro-10-methyl-10-azatetracyclo[9.8.0.0²,⁷.0¹⁴,¹⁹]nonadeca-2,4,6,14,16,18-hexaen-4-ol
SMILES
[H][[email protected]]12CCC3=CC=CC=C3[[email protected]]1([H])C1=CC(O)=C(Cl)C=C1CCN2C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineEcopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineEcopipam may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineEcopipam may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ecopipam.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ecopipam.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ecopipam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Ecopipam.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ecopipam.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ecopipam.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ecopipam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Ecopipam.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ecopipam.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ecopipam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecopipam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ecopipam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ecopipam.Experimental
AmphetamineEcopipam may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ecopipam.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ecopipam.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ecopipam.Vet Approved
AzelastineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ecopipam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ecopipam.Approved
BenzphetamineEcopipam may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ecopipam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ecopipam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ecopipam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ecopipam is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ecopipam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ecopipam.Approved, Investigational
BuprenorphineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecopipam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ecopipam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ecopipam.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ecopipam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ecopipam.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ecopipam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ecopipam.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ecopipam.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Ecopipam.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ecopipam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ecopipam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ecopipam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ecopipam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ecopipam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ecopipam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Chlorphenamine.Approved
ChlorphentermineEcopipam may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecopipam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecopipam.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ecopipam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ecopipam.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ecopipam.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecopipam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ecopipam.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ecopipam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ecopipam.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecopipam.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecopipam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Ecopipam.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ecopipam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Ecopipam.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ecopipam.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ecopipam.Approved, Vet Approved
DextroamphetamineEcopipam may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ecopipam.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ecopipam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ecopipam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ecopipam.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ecopipam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ecopipam is combined with Diethyl ether.Experimental
DiethylpropionEcopipam may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ecopipam.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ecopipam.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ecopipam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ecopipam.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ecopipam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ecopipam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ecopipam.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ecopipam.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ecopipam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ecopipam.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ecopipam.Experimental, Illicit
EfavirenzThe risk or severity of adverse effects can be increased when Ecopipam is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ecopipam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ecopipam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ecopipam is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ecopipam.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ecopipam.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ecopipam.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ecopipam.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ecopipam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ecopipam.Approved
EthanolEcopipam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ecopipam.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ecopipam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ecopipam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ecopipam.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ecopipam.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ecopipam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecopipam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ecopipam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ecopipam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecopipam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ecopipam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ecopipam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ecopipam.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecopipam.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecopipam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ecopipam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ecopipam.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ecopipam.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ecopipam.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ecopipam.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ecopipam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ecopipam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ecopipam.Approved, Illicit
GepefrineEcopipam may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Ecopipam.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ecopipam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ecopipam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecopipam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ecopipam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ecopipam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecopipam.Approved
HydrocodoneEcopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecopipam.Approved, Illicit
HydroxyamphetamineEcopipam may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indiplon.Investigational
Iofetamine I-123Ecopipam may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ecopipam.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ecopipam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecopipam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ecopipam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ecopipam.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ecopipam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ecopipam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ecopipam.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ecopipam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ecopipam.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ecopipam.Approved, Investigational
LisdexamfetamineEcopipam may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Ecopipam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ecopipam.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ecopipam.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ecopipam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ecopipam.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Ecopipam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ecopipam.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ecopipam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ecopipam.Approved
MephedroneEcopipam may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineEcopipam may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecopipam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Meptazinol.Experimental
MequitazineEcopipam may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecopipam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ecopipam.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ecopipam.Approved, Illicit
MethamphetamineEcopipam may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ecopipam.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ecopipam.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ecopipam.Approved
MethotrimeprazineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ecopipam.Approved, Vet Approved
MethoxyphenamineEcopipam may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ecopipam.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ecopipam.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ecopipam.Approved, Investigational
MetyrosineEcopipam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam.Approved, Illicit
MidomafetamineEcopipam may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ecopipam.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Investigational
MirtazapineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAEcopipam may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ecopipam.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ecopipam.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ecopipam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ecopipam.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ecopipam.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ecopipam.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ecopipam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ecopipam.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ecopipam.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ecopipam.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ecopipam.Approved, Illicit
OrphenadrineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ecopipam.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ecopipam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ecopipam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ecopipam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecopipam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ecopipam.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecopipam.Approved
ParaldehydeEcopipam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ecopipam.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ecopipam.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
PerazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ecopipam.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ecopipam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ecopipam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ecopipam.Approved
PhenibutThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ecopipam.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ecopipam.Approved
PhentermineEcopipam may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ecopipam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ecopipam.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ecopipam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Pomalidomide.Approved
PramipexoleEcopipam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ecopipam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ecopipam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ecopipam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ecopipam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ecopipam.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ecopipam.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecopipam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ecopipam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Ecopipam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ecopipam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ecopipam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ecopipam.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ecopipam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ecopipam.Investigational
PseudoephedrineEcopipam may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ecopipam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecopipam.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ecopipam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ecopipam.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecopipam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ecopipam.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecopipam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ritanserin.Investigational
RitobegronEcopipam may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ecopipam.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ecopipam.Vet Approved
RopiniroleEcopipam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecopipam.Approved
RotigotineEcopipam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ecopipam.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecopipam.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ecopipam.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ecopipam.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ecopipam.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecopipam.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ecopipam.Approved, Investigational
SuvorexantEcopipam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ecopipam.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ecopipam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ecopipam.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ecopipam.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ecopipam.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ecopipam.Investigational
ThalidomideEcopipam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecopipam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ecopipam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ecopipam.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ecopipam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ecopipam.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecopipam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ecopipam.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecopipam.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecopipam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ecopipam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Ecopipam.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecopipam.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecopipam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ecopipam.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ecopipam.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ecopipam.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ecopipam is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ecopipam.Approved
XenonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ecopipam.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ecopipam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecopipam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ecopipam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ecopipam.Approved, Investigational
ZolpidemEcopipam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ecopipam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ecopipam.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ecopipam.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
97053
BindingDB
50004823
ChEBI
93645
ChEMBL
CHEMBL298406

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLesch-Nyhan Disease1
1, 2CompletedTreatmentGilles de la Tourette's Syndrome1
2Active Not RecruitingTreatmentGilles de la Tourette's Syndrome1
2CompletedTreatmentPathological Gambling1
2, 3RecruitingTreatmentChildhood-Onset Fluency Disorder / Communication Disorders / Language Disorders / Speech Disorders / Stuttering, Adult1
3TerminatedTreatmentLesch-Nyhan Disease / Self-Injurious Behavior1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0236 mg/mLALOGPS
logP4.28ALOGPS
logP4.07ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)8.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity91.6 m3·mol-1ChemAxon
Polarizability34.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Not Available
Direct Parent
Benzazepines
Alternative Parents
Tetralins / Azepines / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Aryl chlorides / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides
show 1 more
Substituents
Benzazepine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Azepine / Aralkylamine / Aryl chloride / Aryl halide / Benzenoid / Tertiary amine / Tertiary aliphatic amine
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:47 / Updated on October 02, 2017 06:28